CareCloud, Inc. 10-K

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following is a discussion of our consolidated financial condition and results of operations for the years ended December 31, 2025 and 2024 and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Consolidated Financial Statements and related notes beginning on page F-1 of this Annual Report on Form 10-K. Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “ Forward-Looking Statements ” on page 3 of this Annual Report on Form 10-K. 42 Overview The Company is a healthcare information technology company that provides technology-enabled business solutions and Software-as-a-Service offerings (“SaaS”), which are often bundled, but are occasionally provided individually, together with related business services to healthcare providers and hospitals throughout the United States. The SaaS component is not material to the overall contract compared to the stand-alone value of RCM. Our integrated SaaS platform includes technology-enabled revenue cycle management (“RCM”), practice management (“PM”), electronic health records (“EHR”), artificial intelligence (“AI”) tools, business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems. At a high level, these solutions can be categorized as follows: ● Technology-enabled business solutions, which are sometimes provided as individual offerings and often provided in combination with each other, including: ○ RCM services which include end-to-end medical billing, eligibility, analytics, and related services, all of which can be provided utilizing our technology platform or through a third-party system; ○ AI tools designed to serve as a digital healthcare assistant, helping to enhance clinical decision-making, streamline workflows, reduce administrative burdens, optimize revenue management, and promote patient-centered care; ○ EHRs, which are easy to use and sometimes integrated with our business services, and enable our healthcare provider clients to deliver better patient care, streamline their clinical workflows, decrease documentation errors and potentially qualify for government incentives for both inpatient and outpatient services; ○ PM software and related capabilities, which support our clients’ day-to-day business operations within the enterprise-level facilities outpatient service areas and financial workflows, including automated insurance eligibility software, contains a robust billing and claims rules engine and other automated tools designed to maximize reimbursement; ○ RCM Cloud, a highly configurable inpatient revenue cycle management software solution that focuses on up front financial accountability, real-time insurance eligibility checking, robust billing, integrated claims resolution, denial management, collection management, and dynamic work queues designed maximize timely reimbursements; ○ HealthLine, which is a medical supply chain and inventory management system built for healthcare settings enables real-time tracking of supplies, equipment and consumables across multiple locations such as exam rooms, ambulances and storage closets; ○ Marketware, which offers a comprehensive physician strategy suite designed to support healthcare organizations in optimizing physician relationship management, streamlining recruitment and onboarding processes, and leveraging performance analytics. The platform consolidates critical data to enhance referral volume, strengthen provider engagement and drive strategic organizational growth; ○ Wellsoft, a solution for provider workflows in emergency departments and urgent care facilities has seamless integration into all major hospital IT systems and ancillary departments providing real-time patient tracking and instant lab orders, drug interaction checking and pharmacy review; ○ CareVue, a cloud-based EHR software that enhances clinical workflows for small hospitals and inpatient behavioral health facilities, driving efficiencies across inpatient settings through speech-to-text charting, e-prescribing and medication management and secure clinical communications; ○ PXM solutions designed to transform interactions between patients and their clinicians, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services, including contactless digital check-in solutions, messaging and online appointment scheduling tools; ○ CareCloud Wellness, a digital health solution which includes chronic care management interactions with certified care managers and remote patient monitoring which feeds patient data directly to the EHR (and highlights exceptions); and telehealth solutions which allowing healthcare providers to conduct remote patient visits; ○ Business intelligence and healthcare analytics platforms that allow our clients to derive actionable insights from their vast amount of data; ○ Healthcare claims clearinghouse which enables our clients to electronically scrub and submit claims and process payments from insurance companies; ○ Interoperability and data transformation software to support the complex realities of data exchange with healthcare trading partners, including labs, insurance companies, and other healthcare IT vendors; ○ Customized applications, interfaces and a variety of other technology solutions that support our healthcare clients; 43 ○ Professional services consisting of application and advisory services, revenue cycle services, data analytic services and educational training services; ○ Workforce augmentation and on-demand staffing to support our clients as they expand their businesses, seek highly trained personnel, or struggle with staffing shortages; and ○ Managed services which include inpatient and outpatient IT services, government consulting and product development services. ● MAP App is an industry-leading tool for benchmarking and measuring revenue cycle management performance, which was developed by the HFMA and is used by top hospitals and healthcare organizations nationwide. ● Medical practice management services are provided to medical practices. In this service model, we provide the medical practice with appropriate facilities, equipment, supplies, support services, nurses and administrative support staff. We also provide management, bill-paying and financial advisory services. We currently provide services to three pediatric practices which comprises the Medical Practice Management segment. Our offshore operations together accounted for approximately 17% and 15% of total expenses for the years ended December 31, 2025 and 2024, respectively. A significant portion of those expenses were personnel-related costs (approximately 76% and 75% of foreign costs for the years ended December 31, 2025 and 2024, respectively). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. All of the medical billing companies that we have acquired used domestic labor or subcontractors from higher cost locations to provide all or a substantial portion of their services. We are able to achieve significant cost reductions as we shift these labor costs to our offshore operations. Key Performance Measures We consider numerous factors in assessing our performance. Key performance measures used by management include adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share. These key performance measures are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period. These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis, as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes. Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures. Adjusted EBITDA excludes the following amounts which are included in GAAP net income: ● Income tax provision or the cash requirements to pay our taxes; ● Net interest expense or the cash requirements necessary to service interest on principal payments on our debt; ● Foreign currency losses and other non-operating expenses; ● Stock-based compensation expense, which includes cash-settled awards and the related taxes, based on changes in the stock price; ● Depreciation and amortization charges; ● Integration costs, such as severance amounts paid to employees from acquired businesses and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements; and ● Lease termination and restructuring costs. 44 Set forth below is a presentation of our adjusted EBITDA for the years ended December 31, 2025 and 2024: Year Ended December 31, 2025 2024 ($ in thousands) Net revenue $ 120,499 $ 110,837 GAAP net income 10,798 7,851 Provision for income taxes 199 160 Net interest expense 81 812 Foreign exchange loss / other expense 284 335 Stock-based compensation expense 454 115 Depreciation and amortization 14,960 14,142 Transaction and integration costs 619 46 Lease termination and restructuring costs 154 596 Adjusted EBITDA $ 27,549 $ 24,057 Adjusted operating income and adjusted operating margin exclude the following amounts which are included in GAAP operating income: ● Stock-based compensation expense, which includes cash-settled awards and the related taxes, based on changes in the stock price; ● Amortization of purchased intangible assets; ● Integration costs, such as severance amounts paid to employees from acquired businesses and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements; and ● Lease termination and restructuring costs. Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the years ended December 31, 2025 and 2024: Year Ended December 31, 2025 2024 ($ in thousands) Net revenue $ 120,499 $ 110,837 GAAP net income 10,798 7,851 Provision for income taxes 199 160 Net interest expense 81 812 Other expense - net 265 298 GAAP operating income 11,343 9,121 GAAP operating margin 9.4 % 8.2 % Stock-based compensation expense 454 115 Amortization of purchased intangible assets 2,129 1,577 Transaction and integration costs 619 46 Lease termination and restructuring costs 154 596 Non-GAAP adjusted operating income $ 14,699 $ 11,455 Non-GAAP adjusted operating margin 12.2 % 10.3 % Adjusted net income and adjusted net income per share exclude the following amounts which are included in GAAP net income: ● Foreign currency losses and other non-operating expenses; ● Stock-based compensation expense, which includes cash-settled awards and the related taxes, based on changes in the stock price; ● Amortization of purchased intangible assets; ● Integration costs, such as severance amounts paid to employees from acquired businesses and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements; and ● Lease termination and restructuring costs. 45 No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net income to non-GAAP adjusted net income for the years ended December 31, 2025 and 2024: Year Ended December 31, 2025 2024 ($ in thousands) GAAP net income $ 10,798 $ 7,851 Foreign exchange loss / other expense 284 335 Stock-based compensation expense 454 115 Amortization of purchased intangible assets 2,129 1,577 Transaction and integration costs 619 46 Lease termination and restructuring costs 154 596 Non-GAAP adjusted net income $ 14,438 $ 10,520 Year Ended December 31, 2025 2024 GAAP net income (loss) attributable to common shareholders, per share $ 0.10 $ (0.28 ) Impact of preferred stock dividend 0.16 0.76 Net income per end-of-period share 0.26 0.48 Foreign exchange loss / other expense 0.01 0.02 Stock-based compensation expense 0.01 0.01 Amortization of purchased intangible assets 0.05 0.10 Transaction and integration costs 0.01 0.00 Lease termination and restructuring costs 0.00 0.04 Non-GAAP adjusted earnings per share $ 0.34 $ 0.65 End-of-period common shares 42,437,949 16,256,236 For purposes of determining non-GAAP adjusted earnings per share, the Company used the number of common shares outstanding at the end of December 31, 2025 and 2024. Non-GAAP adjusted earnings per share does not take into account dividends on the Preferred Stock. No tax effect has been provided in computing non-GAAP adjusted earnings per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. 46 Consolidated Statements of Operations Data Year Ended December 31, 2025 2024 2023 2022 2021 ($ in thousands, except per share data) Net revenue $ 120,499 $ 110,837 $ 117,059 $ 138,826 $ 139,599 Operating expenses: Direct operating costs 64,456 60,842 70,817 84,434 86,918 Selling and marketing 4,818 6,232 9,650 9,788 8,786 General and administrative 18,386 16,123 21,464 23,820 24,273 Research and development 6,382 3,781 4,736 4,401 4,408 Change in contingent consideration - - - (3,090 ) (2,515 ) Depreciation and amortization 14,960 14,142 14,402 11,725 12,195 Goodwill impairment charges - - 42,000 - - Lease terminations, unoccupied lease charges and restructuring costs 154 596 1,105 1,138 2,005 Total operating expenses 109,156 101,716 164,174 132,216 136,070 Operating income (loss) 11,343 9,121 (47,115 ) 6,610 3,529 Net interest expense (81 ) (812 ) (1,040 ) (364 ) (440 ) Other expense - net (265 ) (298 ) (883 ) (637 ) (96 ) Income (loss) before provision (benefit) for income taxes 10,997 8,011 (49,038 ) 5,609 2,993 Income tax provision (benefit) 199 160 (364 ) 177 157 Net income (loss) $ 10,798 $ 7,851 $ (48,674 ) $ 5,432 $ 2,836 Preferred stock dividend 6,906 12,310 15,674 15,517 14,052 Net income (loss) attributable to common shareholders $ 3,892 $ (4,459 ) $ (64,348 ) $ (10,085 ) $ (11,216 ) Weighted average common shares outstanding: basic 37,792,428 16,146,975 15,669,472 15,109,587 14,541,061 Net income (loss) per common share: basic $ 0.10 $ (0.28 ) $ (4.11 ) $ (0.67 ) $ (0.77 ) Consolidated Balance Sheet Data As of December 31, 2025 2024 2023 2022 2021 ($ in thousands) Cash and restricted cash $ 3,617 $ 5,145 $ 3,331 $ 12,299 $ 10,340 Working capital - net (1) 1,315 5,220 (57 ) 12,255 5,997 Total assets 87,598 71,614 77,826 136,174 140,848 Total liabilities 28,092 21,840 36,109 34,485 42,917 Shareholders’ equity 59,506 49,774 41,717 101,689 97,931 (1) Working capital-net is defined as current assets less current liabilities. Other Financial Data To provide investors with additional insight and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making, we supplement our consolidated financial statements presented on a basis consistent with U.S. generally accepted accounting principles, or GAAP, with adjusted EBITDA, (previously defined), a non-GAAP financial measure of earnings. Year Ended December 31, 2025 2024 2023 2022 2021 ($ in thousands) Adjusted EBITDA $ 27,549 $ 24,057 $ 15,429 $ 22,248 $ 22,119 47 Quarterly Results of Operations December 31, September 30, June 30, March 31, December 31, September 30, June 30, March 31, 2025 2025 2025 2025 2024 2024 2024 2024 ($ in thousands, except per share data) Net revenue $ 34,423 $ 31,067 $ 27,377 $ 27,632 $ 28,239 $ 28,546 $ 28,090 $ 25,962 Operating expenses: Direct operating costs 18,288 16,224 14,480 15,464 15,003 15,420 15,242 15,177 Selling and marketing 1,446 1,123 1,118 1,131 1,423 1,375 1,664 1,770 General and administrative 4,809 4,887 4,358 4,332 3,996 4,378 4,028 3,721 Research and development 2,543 1,584 1,020 1,235 1,013 800 1,055 913 Depreciation and amortization 4,219 4,022 3,382 3,337 3,257 3,241 3,714 3,930 Lease termination and restructuring costs - 17 23 114 91 67 116 322 Total operating expenses 31,305 27,857 24,381 25,613 24,783 25,281 25,819 25,833 Operating income 3,118 3,210 2,996 2,019 3,456 3,265 2,271 129 Net interest income (expense) 4 (52 ) (17 ) (16 ) (48 ) (162 ) (264 ) (338 ) Other (expense) income - net (161 ) (55 ) (35 ) (14 ) (71 ) 60 (294 ) 7 Income (loss) before provision for income taxes 2,961 3,103 2,944 1,989 3,337 3,163 1,713 (202 ) Income tax provision 73 43 42 41 41 41 39 39 Net income (loss) $ 2,888 $ 3,060 $ 2,902 $ 1,948 $ 3,296 $ 3,122 $ 1,674 $ (241 ) Preferred stock dividend 1,365 1,365 1,365 2,811 3,286 3,789 3,923 1,312 Net income (loss) attributable to common shareholders $ 1,523 $ 1,695 $ 1,537 $ (863 ) $ 10 $ (667 ) $ (2,249 ) $ (1,553 ) Net income (loss) per common share: Basic and diluted $ 0.04 $ 0.04 $ 0.04 $ (0.04 ) $ 0.00 $ (0.04 ) $ (0.14 ) $ (0.10 ) Adjusted EBITDA $ 7,692 $ 7,733 $ 6,529 $ 5,595 $ 7,141 $ 6,840 $ 6,389 $ 3,687 Reconciliation of net income (loss) to adjusted EBITDA The following table contains a reconciliation of net income (loss) to adjusted EBITDA by year: Year Ended December 31, 2025 2024 2023 2022 2021 ($ in thousands) Net income (loss) $ 10,798 $ 7,851 $ (48,674 ) $ 5,432 $ 2,836 Depreciation 2,511 2,043 2,001 1,952 1,927 Amortization 12,449 12,099 12,401 9,773 10,268 Foreign exchange loss / other expense 284 335 918 712 241 Net interest expense 81 812 1,040 364 440 Income tax provision (benefit) 199 160 (364 ) 177 157 Stock-based compensation expense, net of restructuring costs 454 115 4,716 4,914 5,396 Transaction and integration costs 619 46 286 876 1,364 Goodwill impairment charges - - 42,000 - - Lease terminations, unoccupied lease charges and restructuring costs 154 596 1,105 1,138 2,005 Change in contingent consideration - - - (3,090 ) (2,515 ) Adjusted EBITDA $ 27,549 $ 24,057 $ 15,429 $ 22,248 $ 22,119 48 The following table contains a reconciliation of net income (loss) to adjusted EBITDA by quarter: December 31, September 30, June 30, March 31, December 31, September 30, June 30, March 31, 2025 2025 2025 2025 2024 2024 2024 2024 ($ in thousands) Net income (loss) $ 2,888 $ 3,060 $ 2,902 $ 1,948 $ 3,296 $ 3,122 $ 1,674 $ (241 ) Depreciation 704 652 594 561 533 504 503 503 Amortization 3,515 3,370 2,788 2,776 2,724 2,737 3,211 3,427 Foreign exchange loss (gain) / other expense 164 60 41 19 91 (57 ) 306 (5 ) Net interest (income) expense (4 ) 52 17 16 48 162 264 338 Income tax provision 73 43 42 41 41 41 39 39 Stock-based compensation expense (benefit), net of restructuring costs 147 88 111 108 306 252 265 (708 ) Transaction and integration costs 205 391 11 12 11 12 11 12 Lease termination and restructuring costs - 17 23 114 91 67 116 322 Adjusted EBITDA $ 7,692 $ 7,733 $ 6,529 $ 5,595 $ 7,141 $ 6,840 $ 6,389 $ 3,687 Key Metrics In addition to the line items in our consolidated financial statements, we regularly review the following key metrics to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, make strategic business decisions, and assess market share trends and working capital needs. We believe information on these metrics is useful for investors to understand the underlying trends in our business. Providers and Practices Served: As of December 31, 2025 and 2024, we provided services to approximately 45,000 and 40,000 providers, respectively, (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 2,900 and 2,600 practices, respectively. In addition, we served approximately 80 clients who were not medical practices, but are service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown. Customer Renewal Rate: Our customer renewal rate measures the percentage of our RCM clients who utilize our technology platform who were a party to a services agreement with us on January 1 of a particular year and continued to operate and be a client on December 31 of the same year. It also includes acquired accounts, if they are a party to a services agreement with the company we acquired and are generating revenue for us, so long as the risk of client loss under the respective purchase agreement has fully shifted to us by January 1 of the particular year. Our renewal rates for 2025 and 2024 were 91% and 95% of the number of practices that renewed, respectively. These renewal percentages are not indicative of the loss of revenue due to non-renewal. Sources of Revenue Revenue: We primarily derive our on-going revenues from technology-enabled business solutions, reported in our Healthcare IT segment, which typically includes revenue cycle management and is billed as a percentage of payments collected by our customers. This fee includes the ability to use our EHR, practice management systems and other software as part of the bundled fee. These solutions accounted for approximately 63% and 67% of our revenues during the years ended December 31, 2025 and 2024, respectively. This includes customers utilizing our proprietary product suites, as well as customers from acquisitions of RCM companies which we are servicing utilizing third-party software. Key drivers of our revenue include growth in the number of providers we are servicing, the number of patients served by those providers, and collections by those providers. It also includes SaaS fees, for clients not utilizing revenue cycle management services. When clients utilize our revenue cycle management services, basic SaaS services are included at no additional charge. Revenue is also generated from coding, credentialing, indexing, transcription and other ancillary services. Our professional services include an extensive set of services including EHR vendor-agnostic optimization and activation, project management, IT transformation, consulting, process improvement, training, education and staffing for large healthcare organizations including health systems and hospitals. Revenue is recorded monthly on either a time and materials or a fixed rate basis for each contract. We also generate revenue from our printing and mailing, group purchasing services and medical practice management services. We earned approximately 1% of our revenue from group purchasing services during the years ended December 31, 2025 and 2024. We earned approximately 12% and 13% of our revenue from medical practice management services during the years ended December 31, 2025 and 2024, respectively. This revenue represents fees based on our actual costs plus a percentage of the operating profit and is reported in our Medical Practice Management segment. 49 Operating Expenses Direct Operating Costs. Direct operating costs consist primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facility lease costs, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the consolidated statements of operations. Operations in our Offshore Offices together accounted for approximately 14% and 13% of direct operating costs for the years ended December 31, 2025 and 2024, respectively. As we grow, we expect to achieve further economies of scale and to see our direct operating costs decrease as a percentage of revenue. Selling and Marketing Expense. Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses, which includes onshore and offshore personnel. General and Administrative Expense. General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, facility lease costs and insurance, software license fees and outside professional fees. Our Offshore Offices accounted for approximately 21% and 22% of general and administrative expenses for the years ended December 31, 2025 and 2024, respectively. Research and Development Expense. Research and development expense consists primarily of personnel-related costs, software expense and third-party contractor costs. Depreciation and Amortization Expense. Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to five years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our medical practice management clients is amortized on a straight-line basis over a period of twelve years. Restructuring Costs. Restructuring costs, primarily consist of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements. Interest and Other Income (Expense). Interest income represents interest earned on temporary cash investments and late fees from customers. Interest expense consists primarily of interest costs related to our line of credit, motor vehicle loans and amortization of deferred financing costs. Other income (expense) results primarily from foreign currency transaction gains (losses). Income Taxes. In preparing our consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company reported GAAP earnings in 2025 and 2024, it has incurred tax losses historically and there is uncertainty regarding future U.S. taxable income, which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of December 31, 2025 and December 31, 2024. For the global intangible low-taxed income (“GILTI”) tax, companies can either account for the GILTI inclusion in the period in which they are incurred or establish deferred tax liabilities for the expected future taxes associated with GILTI. The Company records the GILTI provisions as they are incurred each period. 50 Critical Accounting Policies and Estimates We prepare our consolidated financial statements in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions about future events, and apply judgments that affect the reported amounts of assets, liabilities, revenue, expense and related disclosures. We base our estimates, assumptions and judgments on historical experience, current trends and various other factors that we believe to be reasonable under the circumstances. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. On a regular basis, we review our accounting policies, estimates, assumptions and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. The methods, estimates and judgments that we use in applying our accounting policies have a significant impact on our results of operations. Critical accounting policies are those policies used in the preparation of our consolidated financial statements that require management to make difficult, subjective, or complex adjustments, and to make estimates about the effect of matters that are inherently uncertain. Revenue from Contracts with Customers : We account for revenue in accordance with ASC 606, Revenue from Contracts with Customers . Our revenue recognition policies require us to make significant judgments and estimates, particularly as it relates to revenue cycle management. Under ASC 606, certain significant accounting estimates, such as payment-to-charge ratios, effective billing rates and the estimated contractual payment periods are required to measure the revenue cycle management revenue. We analyze various factors including, but not limited to, contractual terms and conditions, the credit-worthiness of our customers and our pricing policies. Changes in judgment on any of the above factors could materially impact the timing and amount of revenue recognized in a given period. Revenue is recognized as the performance obligations are satisfied. We derive revenue from five primary sources: technology-enabled business solutions, professional services, printing and mailing services, group purchasing services and medical practice management services. All of our revenue arrangements are based on contracts with customers. Most of our contracts with customers contain a single performance obligation. For contracts where we provide multiple services such as where we perform multiple ancillary services, each service represents its own performance obligation. Selling or transaction prices are based on the contractual price for the service, which is consistent with the stand-alone selling price. Technology-enabled business solutions: Our technology-enabled business solutions include our revenue cycle management and SaaS services. Revenue cycle management services are the recurring process of submitting and following up on claims with health insurance companies in order for the healthcare providers to receive payment for the services they rendered, assisted by our proprietary technology. CareCloud typically invoices customers on a monthly basis based on the actual collections received by its customers and the agreed-upon rate in the sales contract. The services include use of practice management software and related tools (on a SaaS basis), electronic health records (on a SaaS basis), medical billing services and use of mobile health solutions. We consider the services to be one performance obligation since the promises are not distinct in the context of the contract. The performance obligation consists of a series of distinct services that are substantially the same and have the same periodic pattern of transfer to our customers. In many cases, our clients may terminate their agreements with 90 days’ notice without cause, thereby limiting the term in which we have enforceable rights and obligations, although this time period can vary between clients. Our payment terms are normally net 30 days. Although our contracts typically have stated terms of one or more years, under ASC 606 our contracts are considered month-to-month and accordingly, there is no financing component. For the majority of our contracts which include revenue cycle management services, the total transaction price is variable because our obligation is to process an unknown quantity of claims, as and when requested by our customers over the contract period. When a contract includes variable consideration, we evaluate the estimate of the variable consideration to determine whether the estimate needs to be constrained; therefore, we include variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with variable consideration is subsequently resolved. Estimates to determine variable consideration such as payment to charge ratios, effective billing rates, and the estimated contractual payment periods are updated at each reporting date. Revenue is recognized over the performance period using the input method. Professional services: Revenues from professional services are recorded as the services are provided as the performance obligations are satisfied over time. Revenue is recorded based on the number of hours incurred and the agreed-upon hourly rate. Invoicing is primarily performed as of the end of each month. 51 Printing and mailing services: The Company provides printing and mailing services for both revenue cycle management customers and a non- revenue cycle management customer, and invoices on a monthly basis based on the number of prints, the agreed-upon rate per print and the postage incurred. The performance obligation is satisfied once the printing and mailing is completed. Group purchasing services: The Company provides group purchasing services which enable medical providers to purchase various vaccines directly from selected pharmaceutical companies at a discounted price. Currently, there are approximately 4,000 medical providers who are members of the program. Revenue is recognized as the vaccine shipments are made to the medical providers. Fees from the pharmaceutical companies are paid either quarterly or annually and the Company adjusts its revenue accrual at the time of payment. The Company makes significant judgments regarding the variable consideration which we expect to be entitled to for the group purchasing services which includes the anticipated shipments to the members enrolled in the program, anticipated volumes of purchases made by the members, and the changes in the number of members. The amounts recorded are constrained by estimates of decreases in shipments and loss of members to avoid a significant revenue reversal in the subsequent period. The only performance obligation is to provide the pharmaceutical companies with the medical providers who want to become members in order to purchase vaccines. The performance obligation is satisfied once the medical provider agrees to purchase a specific quantity of vaccines and the medical provider’s information is forwarded to the vaccine suppliers. The Company records a contract asset for revenue earned and not paid as the ultimate payment is conditioned on achieving certain volume thresholds. Practice management services: We estimate the amount that will be collected on claims submitted to insurance carriers which is used to determine the compensation to be paid to the owners of the managed practices. These compensation amounts reduce the revenue that the Company recognizes since they are deducted from gross billings. The estimate of the amounts to be received from the insurance claims are updated at each reporting period. Although we believe that our approach to estimates and judgments is reasonable, actual results could differ, and we may be exposed to increases or decreases in revenue that could be material. Our estimates of variable consideration may prove to be inaccurate, in which case we may have understated or overstated the revenue recognized in an accounting period. The amount of variable consideration recognized to date that remains subject to estimation is included within the contract asset in the consolidated balance sheets. Goodwill Impairment: Goodwill is evaluated for impairment annually as of October 31 st , referred to as the annual test date. The Company also tests for impairment between annual test dates if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting-unit level. The Company has determined that its business consists of two operating segments and two reporting units (Healthcare IT and Medical Practice Management). Application of the goodwill impairment test requires judgment including the use of a discounted cash flow approach, the trading price of publicly traded stock and the guideline public company method. These analyses require significant assumptions and judgments. These assumptions and judgments include estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, determination of our weighted average cost of capital and the selection of comparable companies and the interpretation of their data. Future business and economic conditions, as well as differences in actual financial results related to any of the assumptions, could materially impact the consolidated financial statements through impairment of goodwill or intangible assets and acceleration of the amortization period of the purchased intangible assets which are finite-lived assets. No impairment charges were recorded during the years ended December 31, 2025 or 2024. Business Combinations: The Company accounts for business combinations under the provisions of ASC 805, Business Combinations , which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed are recorded at the date of acquisition at their respective fair values. The fair value amount assigned to intangible assets is based on an exit price from a market participant’s viewpoint, and utilizes data such as discounted cash flow analysis and replacement cost models. Critical estimates in valuing certain intangible assets include, but are not limited to, historical and projected client retention rates, expected future cash inflows and outflows, discount rates, and estimated useful lives of those intangible assets. ASC 805 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. 52 Results of Operations The following table sets forth our consolidated results of operations as a percentage of total revenue for the years shown. Year Ended December 31, 2025 2024 Net revenue 100.0 % 100.0 % Operating expenses: Direct operating costs 53.5 % 54.9 % Selling and marketing 4.0 % 5.6 % General and administrative 15.3 % 14.5 % Research and development 5.3 % 3.4 % Depreciation and amortization 12.4 % 12.8 % Lease termination and restructuring costs 0.1 % 0.6 % Total operating expenses 90.6 % 91.8 % Operating income 9.4 % 8.2 % Net interest expense (0.1 %) (0.7 %) Other expense - net (0.2 %) (0.3 %) Income before provision for income taxes 9.1 % 7.2 % Income tax provision 0.2 % 0.1 % Net income 8.9 % 7.1 % Comparison of 2025 and 2024 Year Ended December 31, Change 2025 2024 Amount Percent ($ in thousands) Net revenue $ 120,499 $ 110,837 $ 9,662 9 % Net revenue. Net revenue of $120.5 million for the year ended December 31, 2025 increased by $9.7 million or 9% from revenue of $110.8 million for the year ended December 31, 2024. Revenue for the years ended December 31, 2025 and 2024 includes $76.9 million and $73.7 million relating to technology-enabled business solutions, $25.4 million and $18.2 million related to professional services and $13.9 million and $14.4 million for medical practice management services, respectively. Our printing and mailing and group purchasing services aggregated $4.3 million and $4.5 million for the year ended December 31, 2025 and 2024, respectively. During the year ended December 31, 2025 there was approximately $10.5 million of revenue related to the Medsphere acquisition. (Refer to Forward-Looking Statements disclosure on page 3 of this Annual Report on Form 10-K.) Year Ended December 31, Change 2025 2024 Amount Percent ($ in thousands) Direct operating costs $ 64,456 $ 60,842 $ 3,614 6 % Selling and marketing 4,818 6,232 (1,414 ) (23 %) General and administrative 18,386 16,123 2,263 14 % Research and development 6,382 3,781 2,601 69 % Depreciation 2,511 2,043 468 23 % Amortization 12,449 12,099 350 3 % Lease termination and restructuring costs 154 596 (442 ) (74 %) Total operating expenses $ 109,156 $ 101,716 $ 7,440 7 % 53 Direct Operating Costs. Direct operating costs of $64.5 million for the year ended December 31, 2025 increased by $3.6 million or 6% from direct operating costs of $60.8 million for the year ended December 31, 2024. Salary costs increased by $1.0 million primarily due to the Medsphere acquisition. Outsourcing and other customer processing costs increased by $2.4 million and consultancy expenses increased by $270,000. Selling and Marketing Expense. Selling and marketing expense of $4.8 million for the year ended December 31, 2025 decreased by $1.4 million or 23% from selling and marketing expense of $6.2 million for the year ended December 31, 2024. The decrease for the year ended December 31, 2025 was due to lower spending on selling and marketing activities and a reduction in headcount. General and Administrative Expense. General and administrative expense of $18.4 million for the year ended December 31, 2025 increased by $2.3 million or 14% from general and administrative expense of $16.1 million for the year ended December 31, 2024. Salary costs increased by $2.5 million due to the increase in headcount. Legal and professional fees decreased by $794,000. Research and Development Expense. Research and development expense of $6.4 million for the year ended December 31, 2025 increased by $2.6 million or 69% from research and development expense of $3.8 million for the year ended December 31, 2024. The increase was due to an increase in the offshore headcount. During the years ended December 31, 2025 and 2024, the Company capitalized approximately $3.2 million and $5.7 million of development costs, respectively, in connection with its internal-use software. Depreciation Expense. Depreciation expense was $2.5 million for the year ended December 31, 2025 and increased by $468,000 or 23% from depreciation expense of $2.0 million for the year ended December 31, 2024. The increase primarily relates to certain leasehold improvements being capitalized. Amortization Expense. Amortization expense of $12.4 million for the year ended December 31, 2025 increased by $350,000 or 3% from amortization expense of $12.1 million for the year ended December 31, 2024. The increase in amortization expense was due to the amortization of the intangible assets related to the current years’ acquisitions. Lease Termination and Restructuring Costs. During the years ended December 31, 2025 and 2024, the Company recorded approximately $154,000 and $606,000 of restructuring costs, respectively. Restructuring costs consists of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements. During the year ended December 31, 2024, there was a gain on a lease termination of approximately $10,000. Year Ended December 31, Change 2025 2024 Amount Percent ($ in thousands) Interest income $ 206 $ 88 $ 118 134 % Interest expense (287 ) (900 ) 613 68 % Other expense - net (265 ) (298 ) 33 11 % Income tax provision 199 160 39 24 % 54 Interest Income. Interest income of $206,000 for the year ended December 31, 2025 increased by $118,000 or 134% from interest income of $88,000 for the year ended December 31, 2024. The interest income represents late fees from customers and interest earned on temporary cash investments, which increased due to higher cash balances being invested. Interest Expense. Interest expense of $287,000 for the year ended December 31, 2025 decreased by $613,000 or 68% from $900,000 for the year ended December 31, 2024. The decrease in interest expense was due to the decreased use of the line of credit and decreases in the interest rate charged. Interest expense on the line of credit was $152,000 and $649,000 during the years ended December 31, 2025 and 2024, respectively and amortization of deferred financing costs was $44,000 and $127,000 during the years ended December 31, 2025 and 2024, respectively. Other Expense - net. Other expense - net was $265,000 for the year ended December 31, 2025 compared to other expense - net of $298,000 for the year ended December 31, 2024. Other expense primarily represents foreign currency transaction gains and losses and legal settlements made by the Company. Legal and other settlements recorded during the years ended December 31, 2025 and 2024 were approximately $175,000 and $465,000, respectively. There was a foreign exchange loss of $109,000 and a gain of $130,000 for the years ended December 31, 2025 and 2024, respectively. Transaction gains and losses result from revaluing intercompany accounts which are denominated in U.S. dollars that represent amounts receivable/payable between the entities. Whenever the exchange rate varies, the gains and losses are recorded in the consolidated statements of operations. Income Tax Provision. There was a $199,000 provision for income taxes for the year ended December 31, 2025 compared to $160,000 for the year ended December 31, 2024. The income tax expense for the years ended December 31, 2025 and 2024 was $199,000 and $160,000, respectively. There was no deferred tax recorded for the years ended December 31, 2025 and 2024. The provision for 2025 and 2024 primarily relates to state and foreign income taxes. The pre-tax income was $11.0 million and $8.0 million for the years ended December 31, 2025 and 2024, respectively. Although the Company reported GAAP earnings in 2025 and 2024, it has incurred tax losses historically and there is uncertainty regarding future U.S. taxable income, which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at December 31, 2025 and 2024. The Company will maintain a full valuation allowance on deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. The Company has recorded goodwill as a result of its acquisitions. Goodwill is generally not amortized for financial reporting purposes. However, goodwill from asset acquisitions is tax deductible and amortized over 15 years for tax purposes. As such, deferred income tax expense and a deferred tax liability arise as a result of the tax-deductibility of this indefinitely lived asset. The resulting deferred tax liability, which is recorded over the amortization period, has an indefinite life. As of December 31, 2025, the Company has a total federal NOL carry forward of approximately $271 million of which approximately $186 million will expire between 2030 and 2037, and the balance of approximately $85 million has an indefinite life. At December 31, 2025, the Company had federal research and development credit carryforwards of approximately $3.4 million. Out of the total federal NOL carry forward, approximately $237 million is from the CareCloud and Meridian acquisitions and is subject to the federal Section 382 NOL annual usage limitations. The Company has state NOL carry forwards of approximately $214 million, of which $87 million relates to the State of New Jersey. These NOLs expire starting in 2026. 55 Liquidity and Capital Resources During the year ended December 31, 2025, cash flow from operations was $28.6 million and at year-end, the Company had $3.6 million in cash and restricted cash and working capital of $1.3 million. During the year ended December 31, 2024, cash flow from operations was $20.6 million and at year-end, the Company had $5.1 million in cash and working capital of $5.2 million. There were no outstanding bank borrowings at both December 31, 2025 and 2024. The following table summarizes our cash flows for the years presented. Year Ended December 31, Change 2025 2024 Amount Percent ($ in thousands) Net cash provided by operating activities $ 28,561 $ 20,642 $ 7,919 38 % Net cash used in investing activities (24,535 ) (7,406 ) (17,129 ) (231 %) Net cash used in financing activities (5,611 ) (11,256 ) 5,645 50 % Effect of exchange rate changes on cash and restricted cash 57 (166 ) 223 134 % Net (decrease) increase in cash and restricted cash $ (1,528 ) $ 1,814 $ (3,342 ) 184 % The income before income taxes was $11.0 million for the year ended December 31, 2025, which included $15.0 million of non-cash depreciation and amortization. The income before income taxes for the year ended December 31, 2024 was $8.0 million, which included $14.1 million of non-cash depreciation and amortization. We have not been adversely affected by inflation as typically we receive a percentage of the fees our clients collect from our revenue cycle management services. Additionally, our medical practice management contracts are based on our costs plus a percentage of the medical practice’s operating income. We continue to monitor the impact of inflation in order to minimize its effects through pricing strategies, productivity improvements and cost reductions. In the event of inflation, we believe that we will be able to pass on any price increases for fixed rate contracts to our customers, as the prices that we charge are not governed by long-term contracts. The interest rate on our Provident line of credit is based on the secured overnight financing rate which has been declining slightly since the inception of the line of credit. Operating Activities Cash provided by operating activities was $28.6 million and $ 20.6 million during the years ended December 31, 2025 and 2024, respectively. The increase in the net income of $2.9 million included the following changes in non-cash items: an increase in stock-based compensation expense of $339,000 and an increase in depreciation and amortization of $739,000. Revenue increased by $9.7 million for the year ended December 31, 2025 compared to the year ended December 31, 2024. Cash operating expenses increased by $6.6 million for the same period. Accounts receivable increased by $408,000 and $1.2 million for the years ended December 31, 2025 and 2024, respectively. Accounts payable and other liabilities increased by $1.3 million and decreased by $4.7 million for the years ended December 31, 2025 and 2024, respectively. Investing Activities Cash used in investing activities during the year ended December 31, 2025 was $24.5 million , an increase of $17.1 million compared to $7.4 million during the year ended December 31, 2024. This is primarily due to the Company paying $16.5 million for its acquisitions during the year ended December 31, 2025. Capitalized software was $3.2 million and $5.7 million during the years ended December 31, 2025 and 2024, respectively. Purchases of property and equipment were $4.8 million and $1.7 million during the years ended December 31, 2025 and 2024, respectively. Financing Activities Cash used by financing activities during the year ended December 31, 2025 was $5.6 million, compared to $11.3 million for the year ended December 31, 2024. Cash used by financing activities during 2025 includes the payment of dividends on the Preferred Stock of $6.3 million and $620,000 of repayments for debt obligations. Cash used by financing activities during 2024 includes the repayment of the credit line of $10 million and $677,000 of repayments for debt obligations. During the year ended December 31, 2025, the Company borrowed approximately $1.5 million to finance the purchase of an aircraft and several vehicles. There was also $24,000 of payments to settle the tax withholding obligations in 2025 compared to $579,000 in 2024. During the year ended December 31, 2025, the Company borrowed approximately $9.3 million on the line of credit primarily to finance the acquisition of Medsphere and which it repaid by the end of the year. Contractual Obligations and Commitments We have contractual obligations under our line of credit. We also maintain operating leases for property and certain office equipment. We were in compliance with all SVB and Provident covenants in 2025. 56 Off-Balance Sheet Arrangements As of December 31, 2025, and 2024, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. During the first quarter of 2020, a New Jersey corporation, talkMD Clinicians, PA (“talkMD”), was formed by the wife of the Executive Chairman, who is a licensed physician, to provide telehealth services. talkMD was determined to be a variable interest entity (“VIE”) for financial reporting purposes because the entity will be controlled by the Company. As of December 31, 2025, talkMD had not yet commenced operations. The Company made arrangements to have the income tax returns prepared for talkMD and advanced the funds for the required taxes. Cumulatively, the Company has paid approximately $6,500 on behalf of talkMD for income taxes. We do not engage in off-balance sheet financing arrangements. Item 7A. Quantitative and Qualitative Disclosures about Market Risk We are a smaller reporting company as defined by 17 C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K. Item 8. Financial Statements and Supplementary Data See “Index to Consolidated Financial Statements” which appears on page F-1 of this Annual Report on Form 10-K. Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure None.